Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice
Latest Information Update: 30 May 2025
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms QOLIBRI
- Sponsors Janssen-Cilag
Most Recent Events
- 23 May 2025 Planned End Date changed from 30 Jun 2027 to 31 Aug 2027.
- 08 Oct 2024 Planned End Date changed from 31 Dec 2026 to 30 Jun 2027.
- 18 Jun 2024 Planned End Date changed from 30 Sep 2026 to 31 Dec 2026.